Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (NCT03436485)

🧪 Interventions in This Study

• ODM-208 (DRUG)
• Midazolam (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (20 Sites)

• University of Maryland Marlene and Stewart Greenebaum Cancer Center — Baltimore, Maryland
• Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota
• Nebraska Cancer Specialists — Omaha, Nebraska
• University at Buffalo, Kaleida Health Great Lakes Cancer Care Collaborative — Buffalo, New York
• Helsinki University Central Hospital — Helsinki,
• Tampere University Hospital — Tampere,
• Institute Bergonié — Bordeaux,
• Centre Léon Bérard — Lyon,
• Institute Paoli-Calmettes — Marseille,
• Institut de cancérologie Strasbourg Europe — Strasbourg,
• Hopital Foch — Suresnes,
• Institut Gustave Roussy — Villejuif,
• The Rutherford Cancer Centre, North East — Bedlington,
• Velindre Cancer Centre — Cardiff,
• The Beatson West of Scotland Cancer Centre — Glasgow,
• The Rutherford Cancer Centre, North West — Liverpool,
• Royal Marsden Hospital — London,
• Charing Cross Hospital — London,
• The Christie NHS Foundation Trust — Manchester,
• Royal Preston Hospital — Preston,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Prostate Cancer Metastatic

• REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer — New York, New York
• Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer — Duarte, California
• Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer — Victoria, British Columbia
• A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer — Duarte, California
• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) — Orange, California

Explore by condition: All Prostate Cancer Metastatic clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.